Patent intelligence · US
US 7018465
Aerosolized ceramic porcelains and glaze composition
Aerosolized ceramic porcelains and glaze composition
Patent details — US 7018465
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 28, 2006
- Expiration
- Mar 23, 2026
- Applicant
- EnameLite, LLC
- Claims
- 32
- CPC classes
- A61K, A61K6/17, A61K6/20, A61K6/836
Quick answer
US 7018465 (Aerosolized ceramic porcelains and glaze composition) is held by EnameLite, LLC. Status: expired. Granted Mar 28, 2006. Expires Mar 23, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- EnameLite, LLC
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61K, A61K6/17, A61K6/20, A61K6/836
More from EnameLite, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12364693
Methods of treating metabolic diseases with fused bicyclic pyrazoles
granted -
US 12295394
Water-soluble additive composition
granted -
US 12116596
Method and apparatus for improved mesenchymal stem cell harvesting
granted -
US 12016853
Methods of treating RBP4 related diseases with triazolopyridines
granted -
US 11951100
Formulations of RBP4 inhibitors and methods of use
granted -
US 11723873
Oral dosage form of ticagrelor and preparation method thereof
granted -
US 11684596
Antidiabetic pharmaceutical compositions and preparation method thereof
granted -
US 11655454
Method and apparatus for improved mesenchymal stem cell harvesting
granted
Frequently asked questions
What is US patent 7018465?
US 7018465 (Aerosolized ceramic porcelains and glaze composition) is held by EnameLite, LLC. Status: expired. Granted Mar 28, 2006. Expires Mar 23, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7018465?
EnameLite, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 7018465 expire?
Our index shows an expiration date of Mar 23, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.